Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
TNF Pharmaceuticals ( (TNFA) ) just unveiled an update.
On September 4, 2025, TNF Pharmaceuticals announced the closing of a $7 million private placement financing of convertible preferred stock with its largest strategic stockholder and other existing stockholders. This financing, priced at a 44% premium to market, aims to support the company’s development milestones for its newly licensed light-based computing accelerator technology for blockchain. The company also completed transactions involving the issuance of Series H and Series I Convertible Preferred Stock and amended the terms of its Series F and Series F-1 Convertible Preferred Stock, extending their maturity dates and removing amortization payments.
More about TNF Pharmaceuticals
TNF Pharmaceuticals operates in the pharmaceutical industry, focusing on the development of innovative technologies and pharmaceutical candidates. The company is involved in the advancement of isomyosamine and Supera-CBD, and is exploring strategic opportunities to enhance shareholder value.
Average Trading Volume: 598,039
Technical Sentiment Signal: Strong Sell
Current Market Cap: $6.73M
See more insights into TNFA stock on TipRanks’ Stock Analysis page.